Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | LATS1 | O95835 | 3/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PPID | Q08752 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796427 | 0.90 | AAK1 (0.36) | AAK1ACVR1BTGFBR1ACVRL1NAMPT | |
| SCHEMBL4445160 | 0.86 | PIK3CA (0.39) | AAK1MAPKAPK2ACVR1BTGFBR1ACVRL1 | |
| SCHEMBL4439485 | 0.85 | MAP4K1 (0.37) | MAP4K1PPID | |
| SCHEMBL4442417 | 0.82 | PIM2 (0.44) | AAK1 | |
| SCHEMBL4566008 | 0.81 | MAPKAPK2 (0.36) | AAK1MAPKAPK2ACVR1BTGFBR1ACVRL1 | |
| SCHEMBL4433849 | 0.78 | IRAK4 (0.40) | ACVR1BTGFBR1ACVRL1NAMPTGSK3B | |
| SCHEMBL4434968 | 0.78 | AKT1 (0.39) | ACVR1BTGFBR1ACVRL1NAMPTMAP4K1 | |
| SCHEMBL27796407 | 0.76 | GAA (0.38) | AAK1NAMPTLATS1MAP4K1LATS2 | |
| SCHEMBL4438011 | 0.73 | ATF1 (0.42) | AAK1MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL4564286 | 0.73 | KDM4E (0.36) | CFTRPPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | AAK1 269/4885MAPKAPK2 88/4885ACVR1B 2882/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | AAK1 269/4885MAPKAPK2 88/4885ACVR1B 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.